ExpressionEdits is a biotechnology company that uses AI to redesign genes and unlock medicines that were previously hard to make. Nature builds genes with introns, stretches of genetic grammar that help a cell read and process a gene correctly. Synthetic genes usually leave introns out, which can hold back RNA quality and how well a protein is made. ExpressionEdits designs them back in. The company's core technology is the Genetic Syntax Engine, an AI platform that redesigns synthetic genes by restoring their natural intron-exon architecture. Restoring introns improves RNA quality and protein expression and can unlock proteins that could not previously be made at useful levels. The platform works across modalities, including gene therapy, recombinant proteins, antibodies, DNA medicines, DNA vaccines, and in vivo CAR-T, among other applications. ExpressionEdits operates a dual-track business model. It has partnerships with pharmaceutical companies, including one publicly disclosed collaboration with Boehringer Ingelheim. It also develops its own wholly owned internal programs. The partnerships provide validation and near-term revenue. The internal pipeline captures the full value of what the platform can create. ExpressionEdits was founded in 2021 and spun out of Professor Allan Bradley's laboratory at the University of Cambridge. It is based in the greater Cambridge area.